Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEUS Trial of zastaprazan for prevention of upper gastrointestinal bleeding in patients with transient ischemic attack or ischemic stroke on antithrombotic therapy
KCT0012421Phase 3Not yet recruiting
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zastaprazan in upper gastrointestinal bleeding (UGIB), sponsored by Jeil Pharmaceutical Co., Ltd.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
zastaprazan
03
Conditions
upper gastrointestinal bleeding (UGIB)
Beyond the preview
Go deeper on KCT0012421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012421.